Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBellas, Lucía
dc.contributor.authorCamacho-Arteaga, Lina
dc.contributor.authorGiner-Soriano, Maria
dc.contributor.authorPrats Uribe, Albert
dc.contributor.authorGomez-Lumbreras, Ainhoa
dc.contributor.authorAguilera, Cristina
dc.contributor.authorAgustí, Antònia
dc.date.accessioned2025-11-21T09:09:16Z
dc.date.available2025-11-21T09:09:16Z
dc.date.issued2025-12
dc.identifier.citationBellas L, Camacho-Arteaga L, Giner-Soriano M, Albert-Prats-Uribe, Gómez-Lumbreras A, Aguilera C, et al. Real-World Data Insights into Antidepressant Prescription and Adherence During Pregnancy in Catalonia (Spain). Drug Saf. 2025 Dec;48:1353–1364.
dc.identifier.issn1179-1942
dc.identifier.urihttp://hdl.handle.net/11351/14083
dc.descriptionAntidepressant prescription; Antidepressant adherence; Pregnancy
dc.description.abstractBackground: Affective disorders, particularly depression, are common among women of childbearing age, and pregnancy often exacerbates symptoms. Antidepressants are often required for treatment, but adherence during pregnancy is variable. Although some studies suggest potential risks to the foetus, many cannot rule out confounding by indication. In this context, understanding real-world patterns of antidepressant prescription and adherence during pregnancy is essential to inform clinical practice and ensure adequate mental healthcare. Objective: The aim of the present study was to characterise the use of antidepressants in a cohort of pregnant women using electronic health records. Methods: This observational cohort drug-utilisation study assessed antidepressant prescription patterns, adherence and persistence among pregnant women using data from the SIDIAP (Information System for the Development of Research in Primary Care) database in Catalonia from January 2011 to June 2020. Results: Among 99,605 pregnancies, 14.9% involved antidepressant prescriptions, but only 5.8% of these were collected from pharmacies. The median pregnancy duration was 38.4 weeks, and the median maternal age was 33.5 years. Anxiety was the most common health issue associated with an antidepressant prescription. Paroxetine was the most frequently prescribed antidepressant, although sertraline usage increased over time. Antidepressant prescriptions and adherence decreased during pregnancy, with an increase in the postpartum period. About 11.6% of pregnancies involved a concurrent prescription of another antidepressant, and 29.2% of women resumed antidepressant use after pregnancy. Women who initiated antidepressants during pregnancy were more likely to persist with treatment than those with pre-existing prescriptions. Conclusions: Our study describes antidepressant use during pregnancy in Catalonia. It is remarkable that there is a notable gap between antidepressant prescriptions and dispensations. Given the risks of untreated maternal depression, strengthening primary care with adequate resources and personalised support is essential for improving perinatal mental healthcare.
dc.language.isoeng
dc.publisherAdis
dc.relation.ispartofseriesDrug Safety;48
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectEmbaràs
dc.subjectAntidepressius - Ús terapèutic
dc.subjectDepressió psíquica - Tractament
dc.subjectMedicaments - Prescripció
dc.subjectAdherència
dc.subject.meshPregnancy
dc.subject.meshMedication Adherence
dc.subject.meshDrug Prescriptions
dc.subject.meshDepression
dc.subject.meshAntidepressive Agents
dc.subject.mesh/therapeutic use
dc.titleReal-World Data Insights into Antidepressant Prescription and Adherence During Pregnancy in Catalonia (Spain)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s40264-025-01576-z
dc.subject.decsembarazo
dc.subject.decsadhesión a la medicación
dc.subject.decsprescripciones de medicamentos
dc.subject.decsdepresión
dc.subject.decsantidepresivos
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.1007/s40264-025-01576-z
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bellas L, Camacho Arteaga L, Agustí A] Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Farmacologia Clínica, Vall Hebron Institut de Recerca (VHIR) Barcelona, Spain. Barcelona, Spain. [Giner Soriano M] Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Prats Uribe A] Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nufeld Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. [Gómez Lumbreras A] College of Pharmacy, The University of Utah, Salt Lake City, UT, USA. [Aguilera C] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid40632487
dc.identifier.wos001527839900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record